Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New gel implant offers hope for back pain sufferers

NCT ID NCT04984629

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new device called the HYDRAFIL system for people with long-term low back pain from worn-out spinal discs. 35 adults who had not gotten better with standard treatments received the implant. The main goal was to see if the device could be safely placed and help reduce pain and improve daily function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Jan 2022

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Present with predominant low back pain and symptoms of DDD of the lumbar region of at least 6 months duration * Failure to have their symptoms resolve or reduce following 6 months conservative care (pain medication and/or physical therapy) * Male or female patients aged 22 to 80 years, inclusive * Presence of DDD on magnetic resonance imaging (MRI) scan with global disc degeneration. Modified Pfirrmann grades 5 to 8 as characterized by MRI * The presence of one or two symptomatic discs exhibiting degeneration contained within a competent outer annulus as determined by MRI and provocative discography and/or anaesthetic discography at L1-S1 * Patients who are legally competent and able to understand the nature, scope and aim of the clinical investigation * Signed an informed subject consent form in a language in which they are fluent Exclusion Criteria: * History of or current systemic or local infection * Annular tear or defect that shows free contrast extravasation into the epidural space during or after discography * Presence of disc herniation that accounts for the majority of the patient's symptoms * Subjects with Modic type 3 changes * Subjects with trans-endplate disc herniations or Schmorl's nodes * Neurogenic claudication due to spinal stenosis * Previous back surgery at the target level of the lumbar spine * Evidence of severe compression of cauda equina * Spinal segmental instability (spondylolysis or spondylolisthesis: Grade \>1), spinal canal stenosis, isthmus pathology, scoliosis \[Cobb angle \>20 at the incident level\] and other deformity conditions that may compromise the study * Subjects with arachnoiditis * Subjects who are prisoners or wards of the courts * Subjects involved in active litigation including worker's compensation cases * Subjects with low back pain of non-spinal or unknown etiology * Subjects with severe osteoporosis or metabolic bone disease * Subjects who have a history of or are current abusers of alcohol or drugs (using definition criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-V)) * If female, patients who are pregnant or are trying to become pregnant during the course of the trial. (due to risks of additional radiation exposures) * Failure to understand informed consent or participation in any other clinical study * Body Mass index (BMI) greater than 40 * Patients with active tumors in the spinal region * Patients who have been diagnosed to diabetes mellitus * Patients who have a sensitivity or allergy to the implant materials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Degenerative disc disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beam Interventional & Diagnostic Imaging

    Calgary, Alberta, T3K6G4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.